Cargando…
Re-investigating PLK1 inhibitors as antimitotic agents
Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitot...
Autores principales: | Delacour, Quentin, Gavet, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706940/ https://www.ncbi.nlm.nih.gov/pubmed/29209646 http://dx.doi.org/10.1080/23723556.2017.1356430 |
Ejemplares similares
-
BORA-dependent PLK1 regulation: A new weapon for cancer therapy?
por: Cirillo, Luca, et al.
Publicado: (2016) -
Another string to the polo bow: a new mitotic role of PLK1 in centromere protection
por: Olukoga, Tomisin, et al.
Publicado: (2019) -
KAT2-mediated PLK4 acetylation contributes to genomic stability by preserving centrosome number
por: Fournier, Marjorie, et al.
Publicado: (2016) -
Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013) -
Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
por: Lipson, Evan J.
Publicado: (2013)